Impact of early detection and steroid treatment on fetal ventricular heart rate and pacemaker implantation in anti-Ro/SSA positive congenital heart block

被引:0
|
作者
Sonesson, Sven-Erik [1 ,2 ]
Ambrosi, Aurelie [2 ]
Nordenstam, Felicia [1 ,3 ]
Eliasson, Hakan [1 ,3 ]
Wahren-Herlenius, Marie [2 ,4 ]
机构
[1] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden
[2] Karolinska Inst, Dept Med, Div Rheumatol, Stockholm, Sweden
[3] Karolinska Univ Hosp, Dept Pediat Cardiol, Stockholm, Sweden
[4] Univ Bergen, Dept Clin Sci, Broegelmann Res Lab, Bergen, Norway
基金
瑞典研究理事会;
关键词
anti-Ro/SSA; congenital heart block; fluorinated steroid; heart rate; pacemaker; treatment; PR INTERVAL; FETUSES; RISK; AUTOANTIBODIES; SURVEILLANCE; REGISTRY;
D O I
10.1111/aogs.14988
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction We investigated the effects of timing of detection and transplacental fluorinated steroid treatment on ventricular heart rate (HR) and age at pacemaker implantation in fetal third-degree atrioventricular block (AVB). Material and Methods Twenty-five of 31 fetuses diagnosed with Ro/SSA autoantibody-positive AVB II-III at our tertiary fetal cardiology center (2000-2020) and AVB III as final feto-neonatal outcome were reviewed. Results AVB was detected approximately 5 weeks earlier in pregnancy if followed in a surveillance program compared to cases referred from primary care for bradycardia (20.6 [2.3] [mean (SD)] vs. 25.4 [3.2] weeks, p = 0.001). AVB detected before 24 weeks had higher HR than those detected later in gestation (63.3 [6.9] vs. 57.2 [6.9] bpm, p = 0.042), with a larger proportion having HR >60 bpm (80% vs. 33%, p = 0.041). The 17/25 cases that received treatment with fluorinated steroid were diagnosed earlier in gestation, with higher HR at diagnosis (61.7 [7.1] vs. 54.7 [6.3] bpm, p = 0.026), 1-2 weeks after diagnosis/treatment start, and before birth (65.4 [12.4] vs. 54.9 [5.7] bpm, p = 0.030) than untreated cases. Overall, 11 cases were commenced on betamimetics: three at diagnosis and eight at or after the examination made 1-2 weeks after diagnosis/treatment start, without any HR improvement. Two of 24 surviving babies were born preterm, and 4/24 received a neonatal pacemaker. Age at pacemaker implantation correlated significantly with HR before birth (Spearman R 0.57, p = 0.004), and fetuses with HR >60 bpm had a higher rate of pacemaker-free survival at three (90% vs. 40%, p = 0.018) and 12 months of age (80% vs. 13%, p = 0.002). The same trend was observed in pacemaker-free survival at 3 months of age in fluorinated steroid-treated compared to untreated cases (71% vs. 38%, ns). Conclusions Our data confirm that AVB III detected earlier in gestation have a higher HR, and suggest that this higher HR can be successfully maintained to the end of gestation in cases treated with fluorinated steroids. Fetuses with HR >60 bpm before birth had a lower rate of pacemaker implantation at 3 and 12 months of age.
引用
收藏
页码:2433 / 2441
页数:9
相关论文
共 45 条
  • [1] NAFTNet retrospective report on the treatment of anti-Ro/SSA mediated fetal heart block with dexamethasone
    Sunderji, Sherzana
    Peyvandi, Shabnam
    Jaeggi, Edgar
    Szwast, Anita
    Ryan, Greg
    Tessier, Francine
    Siddiqui, Saad
    Cuneo, Bettina
    Sheth, Shreya
    Treadwell, Marjorie
    Frommelt, Michele
    Turan, Shifa
    Copel, Joshua
    Emery, Stephen
    Rand, Larry
    Moon-Grady, Anita J.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2022, 35 (25) : 9263 - 9270
  • [2] Anti-Ro52 antibody level is an important marker of fetal congenital heart block risk in anti-Ro/SSA antibody positive pregnancy
    Miyasato-Isoda, Mai
    Waguri, Masako
    Yamada, Yuko
    Miyano, Akira
    Wada, Yoshinao
    MODERN RHEUMATOLOGY, 2018, 28 (04) : 690 - 696
  • [3] Neurodevelopment in children with and without congenital heart block born to anti-Ro/SSA-positive mothers
    Skog, Amanda
    Tingstrom, Joanna
    Salomonsson, Stina
    Sonesson, Sven-Erik
    Wahren-Herlenius, Marie
    ACTA PAEDIATRICA, 2013, 102 (01) : 40 - 46
  • [4] Maternal Anti-Ro/SSA and Anti-La/SSB Antibodies and Fetal Congenital Heart Block
    Kapur A.
    Dey M.
    Tangri M.
    Bandhu H.C.
    The Journal of Obstetrics and Gynecology of India, 2015, 65 (3) : 193 - 195
  • [5] Anti-Ro (SSA) and anti-La (SSB) antibodies and complete congenital heart block
    Finkelstein, Y
    Adler, Y
    Harel, L
    Nussinovitch, M
    Youinou, P
    ANNALES DE MEDECINE INTERNE, 1997, 148 (03): : 205 - 208
  • [6] Ultrasound Findings in Fetal Congenital Heart Block Associated With Maternal Anti-Ro/SSA and Anti-La/SSB Antibodies
    Lai, Jasmine
    Clark, Toshi J.
    Tan, Justin H.
    Delaney, Shani
    Jolley, Jennifer A.
    ULTRASOUND QUARTERLY, 2015, 31 (01) : 34 - 36
  • [7] Early-Onset Cardiomyopathy After Pacemaker Implanted in a Preterm Infant With Congenital Complete Heart Block and Anti-Ro/SSA Antibodies
    Iqbal, Marium
    Umapathi, Krishna Kishore
    Morales, Raymond
    Mubayed, Lamya
    Bokowski, John W.
    Eltayeb, Osama
    Hoang Nguyen
    TEXAS HEART INSTITUTE JOURNAL, 2021, 48 (02)
  • [8] Outcome in 212 anti-Ro/SSA-positive pregnancies and population-based incidence of congenital heart block
    Skog, Amanda
    Lagnefeldt, Linda
    Conner, Peter
    Wahren-Herlenius, Marie
    Sonesson, Sven-Erik
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2016, 95 (01) : 98 - 105
  • [9] Anti-Ro/SSA autoantibody-positive women's experience of information given on the risk of congenital heart block
    Tingstrom, J.
    Hjelmstedt, A.
    Henriksson, E. Welin
    Ambrosi, A.
    Sonesson, S-E
    Wahren-Herlenius, M.
    LUPUS, 2016, 25 (05) : 536 - 542
  • [10] Subclass distribution of maternal and neonatal Anti-Ro(SSA) and La(SSB) antibodies in congenital heart block
    Tseng, CE
    Caldwell, K
    Feit, S
    Chan, EKL
    Buyon, JP
    JOURNAL OF RHEUMATOLOGY, 1996, 23 (05) : 925 - 932